Charles J Yeo Selected Research

Messenger RNA (mRNA)

1/2022	The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma.
9/2015	Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
2/2014	HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
8/2013	HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.
8/2013	Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
8/2012	HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.
3/2012	Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
8/2011	Angiotensin II type 2 receptor blockade inhibits fatty acid synthase production through activation of AMP-activated protein kinase in pancreatic cancer cells.
11/2010	pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
9/2010	HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles J Yeo Research Topics

Disease

126	Neoplasms (Cancer) 12/2023 - 01/2002
113	Adenocarcinoma 06/2023 - 01/2002
85	Pancreatic Neoplasms (Pancreatic Cancer) 04/2022 - 01/2002
17	Neoplasm Metastasis (Metastasis) 12/2023 - 01/2002
17	Pancreatic Fistula (Pancreatic Fistulas) 01/2023 - 11/2004
15	Carcinoma (Carcinomatosis) 03/2024 - 01/2002
10	Neoplasms, Cystic, Mucinous, and Serous 03/2024 - 01/2002
10	Chronic Pancreatitis 01/2018 - 01/2002
7	Pancreatitis 09/2022 - 03/2002
6	Carcinogenesis 01/2022 - 03/2003
6	Wounds and Injuries (Trauma) 12/2021 - 06/2002
5	Inflammation (Inflammations) 04/2015 - 12/2004
4	Diabetes Mellitus 11/2021 - 12/2004
4	Obesity 01/2021 - 02/2009
4	Breast Neoplasms (Breast Cancer) 04/2013 - 01/2003
4	Fistula 01/2013 - 12/2004
3	Acinar Cell Carcinoma 01/2016 - 03/2002
3	Hemorrhage 01/2014 - 02/2003
3	Disease Progression 09/2008 - 12/2004
3	Abscess 11/2006 - 02/2003
3	Adenoma (Adenomas) 01/2005 - 01/2002
3	Pancreatic Diseases (Pancreatic Disease) 01/2003 - 03/2002
2	Duodenal Obstruction 06/2023 - 08/2008
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2023 - 01/2018
2	Margins of Excision 03/2021 - 01/2018
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2005
2	Esophageal Neoplasms (Esophageal Cancer) 01/2020 - 04/2015
2	Pathologic Constriction (Stenosis) 01/2020 - 05/2006
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2020 - 03/2003
2	Tuberculosis (Tuberculoses) 01/2018 - 02/2005
2	Obstructive Jaundice (Cholestatic Jaundice) 01/2018 - 10/2008
2	Pneumonia (Pneumonitis) 01/2017 - 01/2015
2	Insulinoma 01/2017 - 05/2006

Drug/Important Bio-Agent (IBA)

38	Proteins (Proteins, Gene)FDA Link 06/2023 - 03/2002
18	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2002
14	Messenger RNA (mRNA)IBA 01/2022 - 03/2004
11	Gemcitabine FDA Link 01/2018 - 04/2006
9	OsteopontinIBA 04/2015 - 03/2004
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 03/2002
7	EnzymesIBA 01/2021 - 05/2009
6	AntigensIBA 04/2022 - 01/2003
6	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 07/2008
6	MesothelinIBA 03/2015 - 09/2003
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2010 - 07/2003
6	Tumor Biomarkers (Tumor Markers)IBA 09/2004 - 04/2002
5	Protein Isoforms (Isoforms)IBA 04/2022 - 10/2010
5	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2022 - 09/2008
5	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 05/2007
5	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 08/2011 - 01/2002
5	Nicotine FDA Link 01/2011 - 07/2009
5	fascinIBA 02/2006 - 07/2002
4	Colloids (Colloid)IBA 03/2024 - 01/2002
4	Phosphotransferases (Kinase)IBA 01/2021 - 10/2003
4	MucinsIBA 04/2012 - 01/2002
4	Angiotensin IIIBA 08/2011 - 05/2007
4	RNA (Ribonucleic Acid)IBA 02/2009 - 05/2002
4	Complementary DNA (cDNA)IBA 11/2004 - 04/2002
3	Amylases FDA Link 06/2018 - 05/2007
3	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2018 - 05/2003
3	Cadherins (E-Cadherin)IBA 01/2017 - 09/2010
3	AntibodiesIBA 03/2015 - 02/2006
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2014 - 08/2009
3	ParaffinIBA 07/2012 - 05/2002
3	Formaldehyde (Formol)FDA Link 07/2012 - 05/2002
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2011 - 12/2009
3	SmokeIBA 10/2010 - 07/2009
3	Deoxycytidine KinaseIBA 09/2010 - 04/2006
3	OligonucleotidesIBA 04/2004 - 12/2003
3	beta CateninIBA 09/2003 - 03/2002
2	Folic Acid (Vitamin M)FDA LinkGeneric 06/2023 - 08/2005
2	Insulin (Novolin)FDA Link 01/2023 - 09/2004
2	PlatinumIBA 01/2023 - 01/2014
2	AlbuminsIBA 09/2022 - 01/2021
2	Cancer VaccinesIBA 01/2022 - 02/2011
2	Thymidylate SynthaseIBA 01/2021 - 07/2008
2	poly ADP-ribose glycohydrolaseIBA 01/2021 - 01/2019
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 02/2014
2	ElementsIBA 01/2020 - 02/2014
2	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 08/2013
2	thymoquinoneIBA 01/2016 - 08/2009

Therapy/Procedure

49	Pancreaticoduodenectomy 01/2023 - 09/2002
45	Therapeutics 06/2023 - 11/2002
22	Pancreatectomy 12/2023 - 03/2002
17	Drug Therapy (Chemotherapy) 04/2024 - 02/2005
11	Length of Stay 01/2023 - 02/2003
7	Neoadjuvant Therapy 03/2024 - 08/2009
6	Lymph Node Excision (Lymph Node Dissection) 09/2014 - 09/2002
4	Stents 06/2023 - 05/2005
4	Esophagectomy 01/2020 - 02/2003
4	Operative Time 01/2020 - 12/2004
3	Cholecystectomy 01/2020 - 09/2002
3	Radiotherapy 01/2019 - 10/2005
3	Splenectomy 01/2018 - 08/2013
3	Laparotomy 01/2016 - 01/2002
3	Laparoscopic Cholecystectomy 06/2007 - 06/2002
3	Gastrectomy 12/2005 - 09/2002
2	Patient Readmission 04/2024 - 01/2014
2	Immunotherapy 01/2022 - 02/2011
2	Adjuvant Chemotherapy 11/2021 - 01/2018
2	Pancreaticojejunostomy 01/2017 - 05/2009